Public IVD Companies Report Q4, Full-Year 2022 Earnings

YEAR-END AND Q4 EARNINGS REPORTS FROM MAJOR IN VITRO DIAGNOSTICS (IVD) COMPANIES pointed to a welcome sign of core diagnostic business rebounding. That’s the good news for IVD firms. The bad news? All of the SARS-CoV-2 testing revenue that these companies brought in over the last three years—as clinical laboratories and the general public demanded …

Public IVD Companies Report Q4, Full-Year 2022 Earnings Read More »

To access this post, you must purchase The Dark Report.

Public IVD Companies Report Q4, Full-Year 2022 Earnings

In 2022/Q4, IVD companies see base business rise even as COVID-19 test revenue continues to drop

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month